Table 3

Characteristics of clinically classified IM nonresponders with primary and secondary resistance

CharacteristicsPrimary resistanceSecondary resistanceP*
Quantitative features
    WBC at diagnosisRange: [32.2, 536]; mean, 195; CI: [39.8, 350]Range: [122, 480] mean, 221; CI: [36.7, 406].79
    Age, yRange: [43, 77]; mean, 58; CI: [49.6, 66.4]Range: [29,66]; mean, 51.6; CI: [34.2, 69.0].41
    Mutant BCR-ABL transcripts, percentageRange: [18, 35]; mean, 25.8; CI: [13.5, 38.0]Range: [9, 40]; mean, 22.6; CI: [8.48, 36.7].64
    NA4 (28.6%)0
    No. of colonies as percentage of untreated cells CFC IM 1μMRange: [41.1, 67]; mean, 54.1; CI: [47.1, 61.1]Range: [40.6, 92] mean=70.9; CI: [44.3, 97.4].16
    CFC IM 5μMRange: [36, 56.6]; mean, 47.7; CI: [43.0, 52.5]Range: [34, 64]; mean, 50.3; CI: [36.0, 64.7].66
    CFC IM 10μMRange: [29.1, 61.3]; mean, 44.1; CI: [34.9, 53.3]Range: [20.8, 60.3]; mean, 43.8; CI: [21.0, 66.5].97
    Time from diagnosis to IM treatment, dRange: [7, 302]; mean, 127.4; CI: [12.0, 178.5]Range: [13, 377]; mean, 127; CI: [-66.7, 321].70
Qualitative features
    Sokal risk score.434
        High5 (55.6%)0
        Intermediate3 (33.3%)3 (60%)
        Low1 (11.1%)1 (20%)
        NA01 (20%)
    Sex.21§
        Female5 (55.6%)1 (20%)
        Male4 (44.5%)4 (80%)
    Prior interferon.247§
        No8 (88.9)3 (60%)
        Yes1 (11.1%)2 (40%)
    Prior hydroxyurea1§
        No9 (100%)5 (100%)
        Yes00
    Daily IM dose.177
        400 mg6 (66.7%)2 (40%)
        400-600 mg3 (33.3%)1 (20%)
        400-800 mg02 (40%)
  • * P values were calculated using the Welch 2-sample t test at the 5% significant level under the null hypothesis H0: mean (primary resistance) = mean (secondary resistance).

  • P value of mutant BCR-ABL transcript frequency was calculated after all the missing values were taken out of the sample.

  • Kruskal-Wallis test was used to calculate P values of ordered categorical variable for Sokal risk score and daily IM dose.

  • § Fisher exact test was used to calculate P values of nonordered categorical variable for sex, prior interferon, and prior hydroxyurea.